Acadia pharmaceuticals announces trofinetide new drug submission for treatment of rett syndrome has been accepted for filing and priority review by health canada

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced that health canada has accepted its new drug submission (nds) for trofinetide for the treatment of rett syndrome, a rare neurodevelopmental disorder. health canada has granted priority review for acadia's submission. “rett syndrome is a profoundly debilitating and complex neurodevelopmental disorder that presents differently across patients and can lead to an array of unpredictable symptoms,” said pamela di c.
ACAD Ratings Summary
ACAD Quant Ranking